The AHSN Network has supported many innovators to help advance our health and care system. Find out more about successful innovations supported by the NHS.
Find your nearest AHSN
Partnership between Osler Diagnostics, University of Oxford and the Oxford AHSN secures almost £1 million funding to develop new tests for quicker, cheaper and easier diagnosis of patients with chest pain
Funded by an Innovate UK grant, the Oxford AHSN is working with Osler Diagnostics, a health technology company developing innovative biosensor technology and products. Osler’s main product is a portable, handheld device capable of taking a drop of blood and quickly testing for a panel of biomarkers.
Healthcare tech company’s expansion and Stock Exchange listing enabled by Oxford AHSN expertise
The Oxford-based firm Sensyne Health (formerly Drayson Health) uses artificial intelligence (AI) to develop medicines and aims to improve patient care through the analysis and commercialisation of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts.
AHSN support enables AI company Ufonia to leverage £700,000 of grant funding
Ufonia is an artificially intelligent system that monitors health and wellness through a conversation with a medical device voice ‘chat-bot’. Ufonia can provide autonomous, automated telephone-based clinical follow-up, which is applicable to the capture of patient reported outcome measures in numerous clinical areas.
Point of care blood testing by Specialist Paramedics managing patients presenting with Acute Frailty
A single site quality improvement project, using POC blood tests to help inform decision making for patients >65 presenting to specialist paramedics with acute frailty syndrome, leading to better decision making and at scene discharge rates.
Point of care flu testing in A&E
The Oxford AHSN assisted in setting up the real world evaluation of two different Point of Care (POC) tests for influenza at the Royal Berkshire and High Wycombe hospitals. Both tests resulted in better patient management and outcomes, and health economic evaluation showed savings of £200 per patient tested as well as reduced length of stay.